Shulman DeMeo Asset Management LLC Decreases Stock Holdings in Eli Lilly and Company $LLY

Shulman DeMeo Asset Management LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,795 shares of the company’s stock after selling 106 shares during the quarter. Eli Lilly and Company comprises 0.3% of Shulman DeMeo Asset Management LLC’s portfolio, making the stock its 21st largest position. Shulman DeMeo Asset Management LLC’s holdings in Eli Lilly and Company were worth $1,399,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Carr Financial Group Corp increased its position in shares of Eli Lilly and Company by 2.3% during the second quarter. Carr Financial Group Corp now owns 3,344 shares of the company’s stock valued at $2,607,000 after buying an additional 75 shares during the period. Foster Victor Wealth Advisors LLC increased its position in shares of Eli Lilly and Company by 2.2% during the second quarter. Foster Victor Wealth Advisors LLC now owns 665 shares of the company’s stock valued at $523,000 after buying an additional 14 shares during the period. Evanson Asset Management LLC increased its position in shares of Eli Lilly and Company by 19.0% during the second quarter. Evanson Asset Management LLC now owns 2,035 shares of the company’s stock valued at $1,586,000 after buying an additional 325 shares during the period. StoneCrest Wealth Management Inc. increased its position in shares of Eli Lilly and Company by 2.5% during the second quarter. StoneCrest Wealth Management Inc. now owns 6,262 shares of the company’s stock valued at $4,881,000 after buying an additional 153 shares during the period. Finally, Chronos Wealth Management LLC increased its position in shares of Eli Lilly and Company by 2.5% during the second quarter. Chronos Wealth Management LLC now owns 22,335 shares of the company’s stock valued at $17,411,000 after buying an additional 550 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on LLY shares. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. JPMorgan Chase & Co. reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. HSBC raised shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and raised their target price for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $939.61.

Insider Transactions at Eli Lilly and Company

In other news, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $742.51 on Thursday. The business’s 50 day moving average price is $736.05 and its 200-day moving average price is $768.68. The stock has a market cap of $702.75 billion, a P/E ratio of 48.53, a P/E/G ratio of 1.04 and a beta of 0.47. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $939.30. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.